White Paper: The NDC-12 Revenue Risk

How the zero-prefix collision will disrupt reimbursement, patient access, brand protection and market intelligence — and what commercial leaders must do before 2033.

Most NDC-12 discussions are happening in regulatory affairs and labeling. Commercial leadership has been largely absent from that conversation. That absence has a cost.